Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and the safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .


Clinical Trial Description

The purpose of this study is to investigate the efficacy and safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02996214
Study type Interventional
Source Nanjing Luye Sike Pharmaceutical Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 4
Start date November 2016
Completion date June 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04474119 - KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT04432207 - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT04976647 - A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) In Combination With HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04736173 - Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Phase 3